A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.

Inclusion Criteria: * Willing and able to sign written informed consent prior to study entry. * Male or female, \>18 years of age. * Established diagnosis of type 2 diabetes (documented by either HbA1c 6.5 - 10.0% or a history of type 2 diabetes diagnosis). * Treatment naïve or on active therapy with metformin at a daily dose of 1000-3000mg at screening. Dose of metformin must have been stable for at least 3 months prior to screening. * Patients must have a hematocrit value greater than or equal to 34.0% for females and 40% for males. * Patients must have a hemoglobin value greater than or equal to 11.0 g/dL for females and 13.5 g/dL for males. Exclusion Criteria: * Fasting plasma glucose \>220mg/dl at screening. * Impaired kidney function, epidermal growth factor receptor of \<60mL/min/1.73m2 at screening. * BMI \>40kg/m2. * Elevated liver transaminase \> 3 upper limit of normal at screening. * Ongoing or recent (i.e. \< 3month) treatment with any oral or injectable glucose-lowering drug other than metformin. * Ongoing or recent (i.e. \< 3month) injectable insulin therapy. * Ongoing or recent (i.e. \< 3 month) weight loss interventions (e.g. dietary weight loss programs) or any history of bariatric surgery or any documented weight loss \>5% within previous 6 months. * Ongoing or recent (i.e. \< 3 month) treatment with anorectic drugs, systemic steroids, medications known to affect gastric motility, or any condition known to affect gastro-intestinal integrity and food absorption. * Major medical/surgical event requiring hospitalization in the last 3 months. * Known allergy and intolerance to product components or acetaminophen. * Alcohol intake higher than 2 servings per day. A serving is 0.4dl of strong alcohols, 1dl of red or white wine, or 3dl of beer. * Are unable to comply with protocol procedures in the opinion of the investigator. * Have a hierarchical link with the research team members. * Positive pregnancy test at screening. * Patients who have been dosed in another clinical trial with any investigational drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to screening, or patients currently participating in any investigational trial. * Donation of blood or significant amount of blood loss within 8 weeks prior to screening. Patients must also agree to not donate blood within 8 weeks after their last visit.